Cellectis To Present Data On Its Allogeneic CAR T-Cell Programs At The 19th American Society Of Gene & Cell Therapy Annual Meeting

NEW YORK--(BUSINESS WIRE)--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that data on its engineered allogeneic CAR T-cell programs will be featured in three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting.